Advaxis to Receive $1.7M Through New Jersey Technology

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program

PRINCETON, N.J., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc.  (Nasdaq: ADXS ), a clinical-stage biotechnology company developing cancer immunotherapies, announced it has received preliminary approval for a $1.9M tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program for the year 2014. The Company anticipates that it will be able to transfer this credit and receive approximately $1.7 million in cash in mid-December.

This competitive program enables companies to sell New Jersey tax losses and/or research and development tax credits for at least 80% of the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. This allows biotechnology businesses with NOLs to turn their tax losses and credits into cash proceeds to fund more R&D, buy equipment and/or facilities, or cover other allowable expenditures. The program is administered by the New Jersey Economic Development Authority (NJEDA) and the New Jersey Department of the Treasury's Division of Taxation.

"We are very pleased the NJEDA has preliminarily approved our NOL application as it offers the opportunity to bring approximately $1.7 million of non-dilutive funding to Advaxis," commented Daniel J. O'Connor, CEO of Advaxis. "The State of New Jersey continues to be a strong supporter of the biotechnology industry, which is critical for Advaxis as we rapidly advance the clinical development of our Lm -LLO cancer immunotherapy platform in multiple, high-need cancer indications."

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm -LLO platform technology. The Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm -LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. ("Merck"), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm -LLO cancer immunotherapy, ADXS-PSA, with Merck's PD-1 checkpoint inhibitor Keytruda ® (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm -LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

For more information please visit www.advaxis.com .

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Keytruda is a registered trademark of Merck & Co., Inc.

Company: Advaxis, Inc. Greg Mayes, Executive Vice President and COO 609.452.9813 ext. 102 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646.362.5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 0

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 126

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 81

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 89

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 61

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 95

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 288

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 94

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 153

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
on>

Top 5 Most Recently Viewed Articles

Exploring the Trading Landscape for Bitdeer Technologies

Updated Category News Views 99

Whales Are Bullish on Bitdeer Technologies Large investors, often referred to as whales, have shown a strong bullish sentiment towards Bitdeer Technologies. Recent observations from the options trading history reveal a total of eight significant trades in this period. Examining the nature of these trades indicates that approximately 62% were made with optimistic outlooks,...

Continue Reading
Successful Rafi's Amigos Golf Outing Raises Funds for JROTC

Updated Category News Views 188

Successful Fundraising at Rafi's Amigos Golf Outing On a recent day dedicated to supporting local youth, the Rafi's Amigos Golf Outing took place at Beavercreek Golf Club. Despite early rain, the weather brightened, allowing golfers and supporters to enjoy a seamless day on the course. With 116 participants, this year's event was recognized as a remarkable achievement,...

Continue Reading
Trinity Biotech Launches Innovative CGM Technology in India

Updated Category News Views 138

Trinity Biotech Prepares for CGM Launch in India Trinity Biotech plc (NASDAQ:TRIB), based in Dublin, is ready to make a notable stride in diabetes management with the launch of its advanced Continuous Glucose Monitoring (CGM) technology in India. The company has revealed plans for a crucial in-country study aimed at collecting feedback from diabetes patients and...

Continue Reading
Significant Market Growth for Fiberglass Fabrics Expected Soon

Updated Category News Views 259

Fiberglass Fabrics Market Growth Forecast A new market report reveals that the global fiberglass fabrics market is poised for substantial growth, projected to reach an increase of USD 2.83 billion between 2024 and 2028. This impressive expansion is expected to occur at a compound annual growth rate (CAGR) of 7.5% over the forecast period. The driving forces behind this...

Continue Reading
Earnings Insights for Hess Midstream: Key Metrics to Consider

Updated Category News Views 206

Anticipating Hess Midstream's Earnings Results Hess Midstream (NYSE:HESM) is gearing up to release its quarterly earnings report soon, poised to share vital insights that could impact investor sentiment. As the anticipation builds, understanding what to expect is crucial for current and prospective investors alike. Projected Earnings and Market Expectations Analysts are...

Continue Reading